The Diabetogenic Effect of Statin Use May Interact With Polygenic Risk Scores for Type 2 Diabetes.

Abstract

Statins are essential in the prevention of cardiovascular disease; however, their association with type 2 diabetes (T2DM) risk is concerning. We examined whether genetic susceptibility to T2DM modifies the association between regular statin use and T2DM risk. This study included 447,176 individuals from the UK Biobank without baseline diabetes or major cardiovascular disease. Statin use was recorded at baseline, and T2DM incidence was determined using clinical records. Polygenic risk scores (PRS) for T2DM risk were provided by the UK Biobank. Using propensity scores adjusted for age, sex, body mass index, and comorbidities, 14,831 statin users were matched with 37,060 non-users. Cox proportional hazards models were used to estimate the interaction effect of statin use and PRS on T2DM incidence, adjusting for key confounders. In the propensity-matched cohort, 3,675 of 51,891 participants developed T2DM over a mean follow-up period of 13.7 years. Within the top 5% of the PRS distribution, per 1,000 person-years, the incidence of T2DM was 15.42 for statin users versus 12.18 for non-users. Among the lowest 5%, the incidence was 1.9 for statin users and 1.65 for non-users. Based on the Cox proportional hazards model, regular statin use was associated with a 1.239-fold increased T2DM risk (95% confidence interval [CI], 1.152 to 1.333). Furthermore, PGS exhibited a significant multiplicative interaction with regular statin use (odds ratio, 1.102; 95% CI, 1.024 to 1.186). PRS may help identify individuals particularly susceptible to the diabetogenic effects of statins, providing a potential path for personalized cardiovascular disease management.